Immune checkpoint blockade PD-1 therapy for primary liver cancer: incidence and influencing factors of thyroid dysfunction
2022 · Infectious Agents and Cancer · 3 citations
https://doi.org/10.1186/s13027-022-00476-6
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
6
Papers
4
Citations
1
h-index
0
i10-index
Huili Wu is an academic researcher from Beijing YouAn Hospital. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Neuroendocrine Tumor Research Advances & Lung Cancer Research Studies. The author has an h-index of 1, co-authored 6 publications.
Click to start Chat